ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Swissmedic accepts review of Takeda and TiGenix’s file on Cx601
pharmaceutical-technology
June 28, 2017The Swiss Agency for Therapeutic Products (Swissmedic) has accepted a review of Takeda and TiGenix’s file on investigational compound Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease.
Pharma Sources Insight January 2025
